Jump to content
RemedySpot.com

4 New HCV Abstracts

Rate this topic


Recommended Posts

Posted

J Hepatol. 2010 Nov 24. [Epub ahead of print]

Predictors and effects of alcohol use on liver function among young HCV-infected

injection drug users in a behavioral intervention.

Drumright LN, Hagan H, DL, Latka MH, Golub ET, Garfein RS, Clapp JD,

JV, Bonner S, Kapadia F, Thiel TK, Strathdee SA.

At the time of work on study: University of California, San Diego, Department of

Medicine, Division of Global Public Health, La Jolla, CA.

Abstract

BACKGROUND & AIMS: Hepatitis C virus (HCV) screening can provide opportunities

to reduce disease progression through counseling against alcohol use, but

empirical data on this issue are sparse. We determined the efficacy of a

behavioral intervention in reducing alcohol use among young, HCV-infected

injection drug users (IDUs) (n=355) and assessed whether changes in liver

enzymes were associated with changes in alcohol consumption.

METHODS: Both the intervention and attention-control groups were counseled to

avoid alcohol use, but the intervention group received enhanced counseling.

Logistic regression, ANOVA, and continuous time Markov models were used to

identify factors associated with alcohol use, changes in mean ALT and AST levels

and change in alcohol use post-intervention.

RESULTS: Six months post-intervention, alcohol abstinence increased 22.7% in

both groups, with no difference by intervention arm. Transition from alcohol use

to abstinence was associated with a decrease in liver enzymes, with a marginally

greater decrease in the intervention group (p=0.05 for ALT; p=0.06 for AST). In

multivariate Markov models, those who used marijuana transitioned from alcohol

abstinence to consumption more rapidly than non-users (RR=3.11); those who were

homeless transitioned more slowly to alcohol abstinence (RR=0.47); and those who

had ever received a clinical diagnosis of liver disease transitioned more

rapidly to abstinence (RR=1.88).

CONCLUSIONS: Although, behavioral counseling to reduce alcohol consumption among

HCV-infected IDUs had a modest effect, reductions in alcohol consumption were

associated with marked improvements in liver function. Interventions to reduce

alcohol use among HCV-infected IDUs may benefit from being integrated into

clinical care and monitoring of HCV infection.

Copyright © 2010. Published by Elsevier B.V.

PMID: 21145862 [PubMed - as supplied by publisher]

Related citations

J Hepatol. 2010 Nov 23. [Epub ahead of print]

Role of a cirrhosis risk score for the early prediction of fibrosis progression

in hepatitis C patients with minimal liver disease.

Trépo E, Potthoff A, Pradat P, Bakshi R, Young B, Lagier R, Moreno C, Verset L,

Cross R, Degré D, Lemmers A, Gustot T, Berthillon P, Rosenberg W, Trépo C,

Sninsky J, Adler M, Wedemeyer H.

Laboratory of Experimental Gastroenterology, Université Libre de Bruxelles,

Brussels, Belgium; Department of Gastroenterology, Hepatopancreatology and

Digestive Oncology, Erasme Hospital, Université libre de Bruxelles, Brussels,

Belgium.

Abstract

BACKGROUND AND AIMS: Fibrosis progression in patients with chronic hepatitis C

(CHC) is highly variable. A Cirrhosis Risk Score (CRS) based on seven genetic

variants has been recently developed for identifying patients at risk for

cirrhosis. The objective of this study was to assess the role of the CRS for the

early prediction of fibrosis progression in CHC patients with mild liver

fibrosis. In addition, we evaluated the potential benefit, for prediction

accuracy, of a recently described non-invasive fibrosis staging assay, the

Enhanced Liver Fibrosis (ELF) test.

METHODS: Two separate cohorts of HCV patients (Brussels, Belgium/Hannover,

Germany) were retrospectively analyzed. Only patients with a fibrosis Ishak or

METAVIR score of F0-F1 at baseline were included. Patients were classified as

progressors if they showed an increase >=2 fibrosis stages at the second

histological evaluation after a follow-up >=5 years. The CRS was calculated

locally. Genotyping was performed by PCR and oligonucleotide ligation with the

resulting signal detected with a Luminex® 200TM and computer analysis.

RESULTS: In Brussels, 12/25 patients progressed (48%); similarly in Hannover,

16/31 (52%) patients progressed. In both sample sets, the CRS was significantly

associated with fibrosis progression (p=0.050 in Brussels; p=0.018 in Hannover).

The ELF test was only a significant predictor in Hannover (p=0.015). In

multivariate analysis the CRS remained the only variable associated with

fibrosis progression (Odds-ratio= 2.23, 95%CI 1.21-4.11 p=0.01).

CONCLUSIONS: Although conducted on a limited number of patients, this study in

two independent centres confirms that the CRS predicts fibrosis progression in

initially mild CHC.

Copyright © 2010. Published by Elsevier B.V.

PMID: 21145859 [PubMed - as supplied by publisher]

Related citations

J Hepatol. 2010 Nov 23. [Epub ahead of print]

Low Dose Ribavirin for Treatment of HCV Infected Thalassemia Major Patients; New

Indications for Combination Therapy.

Tabatabaei SV, Alavian SM, Keshvari M, Behnava B, Miri SM, Elizee PK, Zamani F,

Kafi-Abad SA, Gharehbaghian A, Hajibeigy B, Lankarani KB.

Baqiyatallah University of Medical Sciences, Baqiyatallah Research Center for

Gastroenterology and Liver Disease, Tehran, Iran.

Abstract

BACKGROUND AND AIMS: Treatment guidelines contraindicate ribavirin for treatment

of hepatitis C virus (HCV) infection in thalassemia major patients.

Nevertheless, the current evidence suggests that ribavirin might be tolerated by

these patients. Despite this evidence, low dose ribavirin combination therapy

has not been compared with peginterferon monotherapy in these patients so far.

MATERIAL AND METHODS: Two hundred eighty thalassemia patients with detectable

HCV-RNA PCR (⩾50 IU/mL) and liver histology consistent with chronic HCV

infection were self-assigned to receive peginterferon alfa-2a (n=81) monotherapy

or its combination therapy with ribavirin, 600-800 mg QD, according to

hemoglobin levels (n=199). Treatment experienced patients were eligible for this

study.

RESULTS: Sustained virological response (SVR) was significantly higher in

patients who received ribavirin (51% vs. 38% P=0.02). In multivariate

regression, OR of ribavirin for prediction of SVR was 2.2 (95% CI 1.24-3.91).

The SVR was significantly higher in the ribavirin group in subgroups of patients

with more than 24 years of age, elevated ALT, ferritin<2006 ng/mL, previous

treatment failure, genotype 1, positive history of splenectomy, fibrosis score

of 0-4 HAI and viral load<600,000 IU/mL. Treatment discontinuations due to the

safety concerns were comparable between the treatment groups (6.5 and 8%).

Furthermore, transfusion intervals were almost halved in patients who received

low dose ribavirin.

CONCLUSION: According to the present study, adult thalassemia patients with HCV

infection can be treated successfully with low dose ribavirin. Hence, we

strongly advise combination therapy in thalassemia patients with aforementioned

clinical characteristics. Moreover, ribavirin does not seem to be beneficial in

thalassemia patients below 18 years of age.

Copyright © 2010. Published by Elsevier B.V.

PMID: 21145858 [PubMed - as supplied by publisher]

Related citations

J Hepatol. 2010 Nov 23. [Epub ahead of print]

Rapid Virological Response Is the Most Important Predictor of Sustained

Virological Response Across Genotypes in Patients with Chronic Hepatitis C Virus

Infection.

Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S.

University of North Carolina, Chapel Hill, USA.

Abstract

The probability of response to peginterferon and ribavirin is associated with

numerous host and virological factors. Attainment of a rapid virological

response (RVR), defined as undetectable HCV RNA at week 4 during treatment with

peginterferon and ribavirin, is highly predictive of sustained virological

response (SVR). The aim of the present study was to determine the relative

importance of the kinetics of antiviral response compared to baseline host and

virological factors for predicting SVR.

METHODS: A retrospective analysis of 1,383 patients, encompassing genotypes 1-4,

treated with peginterferon alfa-2a and ribavirin was performed. Baseline

characteristics were compared across HCV genotypes and pretreatment factors

associated with RVR were identified. The relative significance of RVR compared

to other baseline factors for predicting SVR was analyzed by multiple logistic

regression analysis.

RESULTS: RVR was achieved by 16% of patients with genotype 1 and 71% and 60% of

those with genotype 2 and 3, respectively. Among patients who achieved RVR, the

rate of SVR was high across all genotypes and ranged from 88% to 100% (genotypes

1-4). Baseline factors predictive of RVR included genotype, younger age, lower

initial viral load, higher ALT ratio, absence of advanced fibrosis, and younger

age. Notably, the presence of RVR generated the highest odds ratio (5.47, 95%

confidence interval 3.97-7.52) for predicting SVR in multiple logistic

regression analysis of these factors.

CONCLUSIONS: Attainment of RVR varies by genotype and is associated with several

baseline factors. Patients who achieve RVR have the highest rates of SVR,

regardless of genotype. These findings have important implications for

predicting and managing response-guided combination antiviral therapies.

Copyright © 2010. Published by Elsevier B.V.

PMID: 21145856 [PubMed - as supplied by publisher]

Posted

J Hepatol. 2010 Nov 24. [Epub ahead of print]

Predictors and effects of alcohol use on liver function among young HCV-infected

injection drug users in a behavioral intervention.

Drumright LN, Hagan H, DL, Latka MH, Golub ET, Garfein RS, Clapp JD,

JV, Bonner S, Kapadia F, Thiel TK, Strathdee SA.

At the time of work on study: University of California, San Diego, Department of

Medicine, Division of Global Public Health, La Jolla, CA.

Abstract

BACKGROUND & AIMS: Hepatitis C virus (HCV) screening can provide opportunities

to reduce disease progression through counseling against alcohol use, but

empirical data on this issue are sparse. We determined the efficacy of a

behavioral intervention in reducing alcohol use among young, HCV-infected

injection drug users (IDUs) (n=355) and assessed whether changes in liver

enzymes were associated with changes in alcohol consumption.

METHODS: Both the intervention and attention-control groups were counseled to

avoid alcohol use, but the intervention group received enhanced counseling.

Logistic regression, ANOVA, and continuous time Markov models were used to

identify factors associated with alcohol use, changes in mean ALT and AST levels

and change in alcohol use post-intervention.

RESULTS: Six months post-intervention, alcohol abstinence increased 22.7% in

both groups, with no difference by intervention arm. Transition from alcohol use

to abstinence was associated with a decrease in liver enzymes, with a marginally

greater decrease in the intervention group (p=0.05 for ALT; p=0.06 for AST). In

multivariate Markov models, those who used marijuana transitioned from alcohol

abstinence to consumption more rapidly than non-users (RR=3.11); those who were

homeless transitioned more slowly to alcohol abstinence (RR=0.47); and those who

had ever received a clinical diagnosis of liver disease transitioned more

rapidly to abstinence (RR=1.88).

CONCLUSIONS: Although, behavioral counseling to reduce alcohol consumption among

HCV-infected IDUs had a modest effect, reductions in alcohol consumption were

associated with marked improvements in liver function. Interventions to reduce

alcohol use among HCV-infected IDUs may benefit from being integrated into

clinical care and monitoring of HCV infection.

Copyright © 2010. Published by Elsevier B.V.

PMID: 21145862 [PubMed - as supplied by publisher]

Related citations

J Hepatol. 2010 Nov 23. [Epub ahead of print]

Role of a cirrhosis risk score for the early prediction of fibrosis progression

in hepatitis C patients with minimal liver disease.

Trépo E, Potthoff A, Pradat P, Bakshi R, Young B, Lagier R, Moreno C, Verset L,

Cross R, Degré D, Lemmers A, Gustot T, Berthillon P, Rosenberg W, Trépo C,

Sninsky J, Adler M, Wedemeyer H.

Laboratory of Experimental Gastroenterology, Université Libre de Bruxelles,

Brussels, Belgium; Department of Gastroenterology, Hepatopancreatology and

Digestive Oncology, Erasme Hospital, Université libre de Bruxelles, Brussels,

Belgium.

Abstract

BACKGROUND AND AIMS: Fibrosis progression in patients with chronic hepatitis C

(CHC) is highly variable. A Cirrhosis Risk Score (CRS) based on seven genetic

variants has been recently developed for identifying patients at risk for

cirrhosis. The objective of this study was to assess the role of the CRS for the

early prediction of fibrosis progression in CHC patients with mild liver

fibrosis. In addition, we evaluated the potential benefit, for prediction

accuracy, of a recently described non-invasive fibrosis staging assay, the

Enhanced Liver Fibrosis (ELF) test.

METHODS: Two separate cohorts of HCV patients (Brussels, Belgium/Hannover,

Germany) were retrospectively analyzed. Only patients with a fibrosis Ishak or

METAVIR score of F0-F1 at baseline were included. Patients were classified as

progressors if they showed an increase >=2 fibrosis stages at the second

histological evaluation after a follow-up >=5 years. The CRS was calculated

locally. Genotyping was performed by PCR and oligonucleotide ligation with the

resulting signal detected with a Luminex® 200TM and computer analysis.

RESULTS: In Brussels, 12/25 patients progressed (48%); similarly in Hannover,

16/31 (52%) patients progressed. In both sample sets, the CRS was significantly

associated with fibrosis progression (p=0.050 in Brussels; p=0.018 in Hannover).

The ELF test was only a significant predictor in Hannover (p=0.015). In

multivariate analysis the CRS remained the only variable associated with

fibrosis progression (Odds-ratio= 2.23, 95%CI 1.21-4.11 p=0.01).

CONCLUSIONS: Although conducted on a limited number of patients, this study in

two independent centres confirms that the CRS predicts fibrosis progression in

initially mild CHC.

Copyright © 2010. Published by Elsevier B.V.

PMID: 21145859 [PubMed - as supplied by publisher]

Related citations

J Hepatol. 2010 Nov 23. [Epub ahead of print]

Low Dose Ribavirin for Treatment of HCV Infected Thalassemia Major Patients; New

Indications for Combination Therapy.

Tabatabaei SV, Alavian SM, Keshvari M, Behnava B, Miri SM, Elizee PK, Zamani F,

Kafi-Abad SA, Gharehbaghian A, Hajibeigy B, Lankarani KB.

Baqiyatallah University of Medical Sciences, Baqiyatallah Research Center for

Gastroenterology and Liver Disease, Tehran, Iran.

Abstract

BACKGROUND AND AIMS: Treatment guidelines contraindicate ribavirin for treatment

of hepatitis C virus (HCV) infection in thalassemia major patients.

Nevertheless, the current evidence suggests that ribavirin might be tolerated by

these patients. Despite this evidence, low dose ribavirin combination therapy

has not been compared with peginterferon monotherapy in these patients so far.

MATERIAL AND METHODS: Two hundred eighty thalassemia patients with detectable

HCV-RNA PCR (⩾50 IU/mL) and liver histology consistent with chronic HCV

infection were self-assigned to receive peginterferon alfa-2a (n=81) monotherapy

or its combination therapy with ribavirin, 600-800 mg QD, according to

hemoglobin levels (n=199). Treatment experienced patients were eligible for this

study.

RESULTS: Sustained virological response (SVR) was significantly higher in

patients who received ribavirin (51% vs. 38% P=0.02). In multivariate

regression, OR of ribavirin for prediction of SVR was 2.2 (95% CI 1.24-3.91).

The SVR was significantly higher in the ribavirin group in subgroups of patients

with more than 24 years of age, elevated ALT, ferritin<2006 ng/mL, previous

treatment failure, genotype 1, positive history of splenectomy, fibrosis score

of 0-4 HAI and viral load<600,000 IU/mL. Treatment discontinuations due to the

safety concerns were comparable between the treatment groups (6.5 and 8%).

Furthermore, transfusion intervals were almost halved in patients who received

low dose ribavirin.

CONCLUSION: According to the present study, adult thalassemia patients with HCV

infection can be treated successfully with low dose ribavirin. Hence, we

strongly advise combination therapy in thalassemia patients with aforementioned

clinical characteristics. Moreover, ribavirin does not seem to be beneficial in

thalassemia patients below 18 years of age.

Copyright © 2010. Published by Elsevier B.V.

PMID: 21145858 [PubMed - as supplied by publisher]

Related citations

J Hepatol. 2010 Nov 23. [Epub ahead of print]

Rapid Virological Response Is the Most Important Predictor of Sustained

Virological Response Across Genotypes in Patients with Chronic Hepatitis C Virus

Infection.

Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S.

University of North Carolina, Chapel Hill, USA.

Abstract

The probability of response to peginterferon and ribavirin is associated with

numerous host and virological factors. Attainment of a rapid virological

response (RVR), defined as undetectable HCV RNA at week 4 during treatment with

peginterferon and ribavirin, is highly predictive of sustained virological

response (SVR). The aim of the present study was to determine the relative

importance of the kinetics of antiviral response compared to baseline host and

virological factors for predicting SVR.

METHODS: A retrospective analysis of 1,383 patients, encompassing genotypes 1-4,

treated with peginterferon alfa-2a and ribavirin was performed. Baseline

characteristics were compared across HCV genotypes and pretreatment factors

associated with RVR were identified. The relative significance of RVR compared

to other baseline factors for predicting SVR was analyzed by multiple logistic

regression analysis.

RESULTS: RVR was achieved by 16% of patients with genotype 1 and 71% and 60% of

those with genotype 2 and 3, respectively. Among patients who achieved RVR, the

rate of SVR was high across all genotypes and ranged from 88% to 100% (genotypes

1-4). Baseline factors predictive of RVR included genotype, younger age, lower

initial viral load, higher ALT ratio, absence of advanced fibrosis, and younger

age. Notably, the presence of RVR generated the highest odds ratio (5.47, 95%

confidence interval 3.97-7.52) for predicting SVR in multiple logistic

regression analysis of these factors.

CONCLUSIONS: Attainment of RVR varies by genotype and is associated with several

baseline factors. Patients who achieve RVR have the highest rates of SVR,

regardless of genotype. These findings have important implications for

predicting and managing response-guided combination antiviral therapies.

Copyright © 2010. Published by Elsevier B.V.

PMID: 21145856 [PubMed - as supplied by publisher]

Posted

J Hepatol. 2010 Nov 24. [Epub ahead of print]

Predictors and effects of alcohol use on liver function among young HCV-infected

injection drug users in a behavioral intervention.

Drumright LN, Hagan H, DL, Latka MH, Golub ET, Garfein RS, Clapp JD,

JV, Bonner S, Kapadia F, Thiel TK, Strathdee SA.

At the time of work on study: University of California, San Diego, Department of

Medicine, Division of Global Public Health, La Jolla, CA.

Abstract

BACKGROUND & AIMS: Hepatitis C virus (HCV) screening can provide opportunities

to reduce disease progression through counseling against alcohol use, but

empirical data on this issue are sparse. We determined the efficacy of a

behavioral intervention in reducing alcohol use among young, HCV-infected

injection drug users (IDUs) (n=355) and assessed whether changes in liver

enzymes were associated with changes in alcohol consumption.

METHODS: Both the intervention and attention-control groups were counseled to

avoid alcohol use, but the intervention group received enhanced counseling.

Logistic regression, ANOVA, and continuous time Markov models were used to

identify factors associated with alcohol use, changes in mean ALT and AST levels

and change in alcohol use post-intervention.

RESULTS: Six months post-intervention, alcohol abstinence increased 22.7% in

both groups, with no difference by intervention arm. Transition from alcohol use

to abstinence was associated with a decrease in liver enzymes, with a marginally

greater decrease in the intervention group (p=0.05 for ALT; p=0.06 for AST). In

multivariate Markov models, those who used marijuana transitioned from alcohol

abstinence to consumption more rapidly than non-users (RR=3.11); those who were

homeless transitioned more slowly to alcohol abstinence (RR=0.47); and those who

had ever received a clinical diagnosis of liver disease transitioned more

rapidly to abstinence (RR=1.88).

CONCLUSIONS: Although, behavioral counseling to reduce alcohol consumption among

HCV-infected IDUs had a modest effect, reductions in alcohol consumption were

associated with marked improvements in liver function. Interventions to reduce

alcohol use among HCV-infected IDUs may benefit from being integrated into

clinical care and monitoring of HCV infection.

Copyright © 2010. Published by Elsevier B.V.

PMID: 21145862 [PubMed - as supplied by publisher]

Related citations

J Hepatol. 2010 Nov 23. [Epub ahead of print]

Role of a cirrhosis risk score for the early prediction of fibrosis progression

in hepatitis C patients with minimal liver disease.

Trépo E, Potthoff A, Pradat P, Bakshi R, Young B, Lagier R, Moreno C, Verset L,

Cross R, Degré D, Lemmers A, Gustot T, Berthillon P, Rosenberg W, Trépo C,

Sninsky J, Adler M, Wedemeyer H.

Laboratory of Experimental Gastroenterology, Université Libre de Bruxelles,

Brussels, Belgium; Department of Gastroenterology, Hepatopancreatology and

Digestive Oncology, Erasme Hospital, Université libre de Bruxelles, Brussels,

Belgium.

Abstract

BACKGROUND AND AIMS: Fibrosis progression in patients with chronic hepatitis C

(CHC) is highly variable. A Cirrhosis Risk Score (CRS) based on seven genetic

variants has been recently developed for identifying patients at risk for

cirrhosis. The objective of this study was to assess the role of the CRS for the

early prediction of fibrosis progression in CHC patients with mild liver

fibrosis. In addition, we evaluated the potential benefit, for prediction

accuracy, of a recently described non-invasive fibrosis staging assay, the

Enhanced Liver Fibrosis (ELF) test.

METHODS: Two separate cohorts of HCV patients (Brussels, Belgium/Hannover,

Germany) were retrospectively analyzed. Only patients with a fibrosis Ishak or

METAVIR score of F0-F1 at baseline were included. Patients were classified as

progressors if they showed an increase >=2 fibrosis stages at the second

histological evaluation after a follow-up >=5 years. The CRS was calculated

locally. Genotyping was performed by PCR and oligonucleotide ligation with the

resulting signal detected with a Luminex® 200TM and computer analysis.

RESULTS: In Brussels, 12/25 patients progressed (48%); similarly in Hannover,

16/31 (52%) patients progressed. In both sample sets, the CRS was significantly

associated with fibrosis progression (p=0.050 in Brussels; p=0.018 in Hannover).

The ELF test was only a significant predictor in Hannover (p=0.015). In

multivariate analysis the CRS remained the only variable associated with

fibrosis progression (Odds-ratio= 2.23, 95%CI 1.21-4.11 p=0.01).

CONCLUSIONS: Although conducted on a limited number of patients, this study in

two independent centres confirms that the CRS predicts fibrosis progression in

initially mild CHC.

Copyright © 2010. Published by Elsevier B.V.

PMID: 21145859 [PubMed - as supplied by publisher]

Related citations

J Hepatol. 2010 Nov 23. [Epub ahead of print]

Low Dose Ribavirin for Treatment of HCV Infected Thalassemia Major Patients; New

Indications for Combination Therapy.

Tabatabaei SV, Alavian SM, Keshvari M, Behnava B, Miri SM, Elizee PK, Zamani F,

Kafi-Abad SA, Gharehbaghian A, Hajibeigy B, Lankarani KB.

Baqiyatallah University of Medical Sciences, Baqiyatallah Research Center for

Gastroenterology and Liver Disease, Tehran, Iran.

Abstract

BACKGROUND AND AIMS: Treatment guidelines contraindicate ribavirin for treatment

of hepatitis C virus (HCV) infection in thalassemia major patients.

Nevertheless, the current evidence suggests that ribavirin might be tolerated by

these patients. Despite this evidence, low dose ribavirin combination therapy

has not been compared with peginterferon monotherapy in these patients so far.

MATERIAL AND METHODS: Two hundred eighty thalassemia patients with detectable

HCV-RNA PCR (⩾50 IU/mL) and liver histology consistent with chronic HCV

infection were self-assigned to receive peginterferon alfa-2a (n=81) monotherapy

or its combination therapy with ribavirin, 600-800 mg QD, according to

hemoglobin levels (n=199). Treatment experienced patients were eligible for this

study.

RESULTS: Sustained virological response (SVR) was significantly higher in

patients who received ribavirin (51% vs. 38% P=0.02). In multivariate

regression, OR of ribavirin for prediction of SVR was 2.2 (95% CI 1.24-3.91).

The SVR was significantly higher in the ribavirin group in subgroups of patients

with more than 24 years of age, elevated ALT, ferritin<2006 ng/mL, previous

treatment failure, genotype 1, positive history of splenectomy, fibrosis score

of 0-4 HAI and viral load<600,000 IU/mL. Treatment discontinuations due to the

safety concerns were comparable between the treatment groups (6.5 and 8%).

Furthermore, transfusion intervals were almost halved in patients who received

low dose ribavirin.

CONCLUSION: According to the present study, adult thalassemia patients with HCV

infection can be treated successfully with low dose ribavirin. Hence, we

strongly advise combination therapy in thalassemia patients with aforementioned

clinical characteristics. Moreover, ribavirin does not seem to be beneficial in

thalassemia patients below 18 years of age.

Copyright © 2010. Published by Elsevier B.V.

PMID: 21145858 [PubMed - as supplied by publisher]

Related citations

J Hepatol. 2010 Nov 23. [Epub ahead of print]

Rapid Virological Response Is the Most Important Predictor of Sustained

Virological Response Across Genotypes in Patients with Chronic Hepatitis C Virus

Infection.

Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S.

University of North Carolina, Chapel Hill, USA.

Abstract

The probability of response to peginterferon and ribavirin is associated with

numerous host and virological factors. Attainment of a rapid virological

response (RVR), defined as undetectable HCV RNA at week 4 during treatment with

peginterferon and ribavirin, is highly predictive of sustained virological

response (SVR). The aim of the present study was to determine the relative

importance of the kinetics of antiviral response compared to baseline host and

virological factors for predicting SVR.

METHODS: A retrospective analysis of 1,383 patients, encompassing genotypes 1-4,

treated with peginterferon alfa-2a and ribavirin was performed. Baseline

characteristics were compared across HCV genotypes and pretreatment factors

associated with RVR were identified. The relative significance of RVR compared

to other baseline factors for predicting SVR was analyzed by multiple logistic

regression analysis.

RESULTS: RVR was achieved by 16% of patients with genotype 1 and 71% and 60% of

those with genotype 2 and 3, respectively. Among patients who achieved RVR, the

rate of SVR was high across all genotypes and ranged from 88% to 100% (genotypes

1-4). Baseline factors predictive of RVR included genotype, younger age, lower

initial viral load, higher ALT ratio, absence of advanced fibrosis, and younger

age. Notably, the presence of RVR generated the highest odds ratio (5.47, 95%

confidence interval 3.97-7.52) for predicting SVR in multiple logistic

regression analysis of these factors.

CONCLUSIONS: Attainment of RVR varies by genotype and is associated with several

baseline factors. Patients who achieve RVR have the highest rates of SVR,

regardless of genotype. These findings have important implications for

predicting and managing response-guided combination antiviral therapies.

Copyright © 2010. Published by Elsevier B.V.

PMID: 21145856 [PubMed - as supplied by publisher]

Posted

J Hepatol. 2010 Nov 24. [Epub ahead of print]

Predictors and effects of alcohol use on liver function among young HCV-infected

injection drug users in a behavioral intervention.

Drumright LN, Hagan H, DL, Latka MH, Golub ET, Garfein RS, Clapp JD,

JV, Bonner S, Kapadia F, Thiel TK, Strathdee SA.

At the time of work on study: University of California, San Diego, Department of

Medicine, Division of Global Public Health, La Jolla, CA.

Abstract

BACKGROUND & AIMS: Hepatitis C virus (HCV) screening can provide opportunities

to reduce disease progression through counseling against alcohol use, but

empirical data on this issue are sparse. We determined the efficacy of a

behavioral intervention in reducing alcohol use among young, HCV-infected

injection drug users (IDUs) (n=355) and assessed whether changes in liver

enzymes were associated with changes in alcohol consumption.

METHODS: Both the intervention and attention-control groups were counseled to

avoid alcohol use, but the intervention group received enhanced counseling.

Logistic regression, ANOVA, and continuous time Markov models were used to

identify factors associated with alcohol use, changes in mean ALT and AST levels

and change in alcohol use post-intervention.

RESULTS: Six months post-intervention, alcohol abstinence increased 22.7% in

both groups, with no difference by intervention arm. Transition from alcohol use

to abstinence was associated with a decrease in liver enzymes, with a marginally

greater decrease in the intervention group (p=0.05 for ALT; p=0.06 for AST). In

multivariate Markov models, those who used marijuana transitioned from alcohol

abstinence to consumption more rapidly than non-users (RR=3.11); those who were

homeless transitioned more slowly to alcohol abstinence (RR=0.47); and those who

had ever received a clinical diagnosis of liver disease transitioned more

rapidly to abstinence (RR=1.88).

CONCLUSIONS: Although, behavioral counseling to reduce alcohol consumption among

HCV-infected IDUs had a modest effect, reductions in alcohol consumption were

associated with marked improvements in liver function. Interventions to reduce

alcohol use among HCV-infected IDUs may benefit from being integrated into

clinical care and monitoring of HCV infection.

Copyright © 2010. Published by Elsevier B.V.

PMID: 21145862 [PubMed - as supplied by publisher]

Related citations

J Hepatol. 2010 Nov 23. [Epub ahead of print]

Role of a cirrhosis risk score for the early prediction of fibrosis progression

in hepatitis C patients with minimal liver disease.

Trépo E, Potthoff A, Pradat P, Bakshi R, Young B, Lagier R, Moreno C, Verset L,

Cross R, Degré D, Lemmers A, Gustot T, Berthillon P, Rosenberg W, Trépo C,

Sninsky J, Adler M, Wedemeyer H.

Laboratory of Experimental Gastroenterology, Université Libre de Bruxelles,

Brussels, Belgium; Department of Gastroenterology, Hepatopancreatology and

Digestive Oncology, Erasme Hospital, Université libre de Bruxelles, Brussels,

Belgium.

Abstract

BACKGROUND AND AIMS: Fibrosis progression in patients with chronic hepatitis C

(CHC) is highly variable. A Cirrhosis Risk Score (CRS) based on seven genetic

variants has been recently developed for identifying patients at risk for

cirrhosis. The objective of this study was to assess the role of the CRS for the

early prediction of fibrosis progression in CHC patients with mild liver

fibrosis. In addition, we evaluated the potential benefit, for prediction

accuracy, of a recently described non-invasive fibrosis staging assay, the

Enhanced Liver Fibrosis (ELF) test.

METHODS: Two separate cohorts of HCV patients (Brussels, Belgium/Hannover,

Germany) were retrospectively analyzed. Only patients with a fibrosis Ishak or

METAVIR score of F0-F1 at baseline were included. Patients were classified as

progressors if they showed an increase >=2 fibrosis stages at the second

histological evaluation after a follow-up >=5 years. The CRS was calculated

locally. Genotyping was performed by PCR and oligonucleotide ligation with the

resulting signal detected with a Luminex® 200TM and computer analysis.

RESULTS: In Brussels, 12/25 patients progressed (48%); similarly in Hannover,

16/31 (52%) patients progressed. In both sample sets, the CRS was significantly

associated with fibrosis progression (p=0.050 in Brussels; p=0.018 in Hannover).

The ELF test was only a significant predictor in Hannover (p=0.015). In

multivariate analysis the CRS remained the only variable associated with

fibrosis progression (Odds-ratio= 2.23, 95%CI 1.21-4.11 p=0.01).

CONCLUSIONS: Although conducted on a limited number of patients, this study in

two independent centres confirms that the CRS predicts fibrosis progression in

initially mild CHC.

Copyright © 2010. Published by Elsevier B.V.

PMID: 21145859 [PubMed - as supplied by publisher]

Related citations

J Hepatol. 2010 Nov 23. [Epub ahead of print]

Low Dose Ribavirin for Treatment of HCV Infected Thalassemia Major Patients; New

Indications for Combination Therapy.

Tabatabaei SV, Alavian SM, Keshvari M, Behnava B, Miri SM, Elizee PK, Zamani F,

Kafi-Abad SA, Gharehbaghian A, Hajibeigy B, Lankarani KB.

Baqiyatallah University of Medical Sciences, Baqiyatallah Research Center for

Gastroenterology and Liver Disease, Tehran, Iran.

Abstract

BACKGROUND AND AIMS: Treatment guidelines contraindicate ribavirin for treatment

of hepatitis C virus (HCV) infection in thalassemia major patients.

Nevertheless, the current evidence suggests that ribavirin might be tolerated by

these patients. Despite this evidence, low dose ribavirin combination therapy

has not been compared with peginterferon monotherapy in these patients so far.

MATERIAL AND METHODS: Two hundred eighty thalassemia patients with detectable

HCV-RNA PCR (⩾50 IU/mL) and liver histology consistent with chronic HCV

infection were self-assigned to receive peginterferon alfa-2a (n=81) monotherapy

or its combination therapy with ribavirin, 600-800 mg QD, according to

hemoglobin levels (n=199). Treatment experienced patients were eligible for this

study.

RESULTS: Sustained virological response (SVR) was significantly higher in

patients who received ribavirin (51% vs. 38% P=0.02). In multivariate

regression, OR of ribavirin for prediction of SVR was 2.2 (95% CI 1.24-3.91).

The SVR was significantly higher in the ribavirin group in subgroups of patients

with more than 24 years of age, elevated ALT, ferritin<2006 ng/mL, previous

treatment failure, genotype 1, positive history of splenectomy, fibrosis score

of 0-4 HAI and viral load<600,000 IU/mL. Treatment discontinuations due to the

safety concerns were comparable between the treatment groups (6.5 and 8%).

Furthermore, transfusion intervals were almost halved in patients who received

low dose ribavirin.

CONCLUSION: According to the present study, adult thalassemia patients with HCV

infection can be treated successfully with low dose ribavirin. Hence, we

strongly advise combination therapy in thalassemia patients with aforementioned

clinical characteristics. Moreover, ribavirin does not seem to be beneficial in

thalassemia patients below 18 years of age.

Copyright © 2010. Published by Elsevier B.V.

PMID: 21145858 [PubMed - as supplied by publisher]

Related citations

J Hepatol. 2010 Nov 23. [Epub ahead of print]

Rapid Virological Response Is the Most Important Predictor of Sustained

Virological Response Across Genotypes in Patients with Chronic Hepatitis C Virus

Infection.

Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S.

University of North Carolina, Chapel Hill, USA.

Abstract

The probability of response to peginterferon and ribavirin is associated with

numerous host and virological factors. Attainment of a rapid virological

response (RVR), defined as undetectable HCV RNA at week 4 during treatment with

peginterferon and ribavirin, is highly predictive of sustained virological

response (SVR). The aim of the present study was to determine the relative

importance of the kinetics of antiviral response compared to baseline host and

virological factors for predicting SVR.

METHODS: A retrospective analysis of 1,383 patients, encompassing genotypes 1-4,

treated with peginterferon alfa-2a and ribavirin was performed. Baseline

characteristics were compared across HCV genotypes and pretreatment factors

associated with RVR were identified. The relative significance of RVR compared

to other baseline factors for predicting SVR was analyzed by multiple logistic

regression analysis.

RESULTS: RVR was achieved by 16% of patients with genotype 1 and 71% and 60% of

those with genotype 2 and 3, respectively. Among patients who achieved RVR, the

rate of SVR was high across all genotypes and ranged from 88% to 100% (genotypes

1-4). Baseline factors predictive of RVR included genotype, younger age, lower

initial viral load, higher ALT ratio, absence of advanced fibrosis, and younger

age. Notably, the presence of RVR generated the highest odds ratio (5.47, 95%

confidence interval 3.97-7.52) for predicting SVR in multiple logistic

regression analysis of these factors.

CONCLUSIONS: Attainment of RVR varies by genotype and is associated with several

baseline factors. Patients who achieve RVR have the highest rates of SVR,

regardless of genotype. These findings have important implications for

predicting and managing response-guided combination antiviral therapies.

Copyright © 2010. Published by Elsevier B.V.

PMID: 21145856 [PubMed - as supplied by publisher]

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...